


PHARMACEUTICAL 2020



International Stem Cell CORP Rank 231 of 362







PHARMACEUTICAL 2020



International Stem Cell CORP Rank 231 of 362

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 506% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 267% points.

The company's Economic Capital Ratio, given in the ranking table, is -267%, being 36% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	3,452
Cost of Goods Sold	3,933
Intangible Assets	1,335
Liabilities, Current	1,913
Liabilities, Non-Current	718
Other Assets	1,165
Other Compr. Net Income	0
Other Expenses	2,685
Other Liabilities	2,577
Other Net Income	1,463
Property and Equipment	668
Research and Development	1,386
Revenues	9,472
Selling, General and Administrative Expense	7,196

Output Variable	Value in 1000 USD
Assets	6,620
Liabilities	5,208
Expenses	15,200
Stockholders Equity	1,412
Net Income	-4,265
Comprehensive Net Income	-4,265
Economic Capital Ratio	-267%

